CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy

Area of Science:

• Biotechnology
• Immunology
• Genetics

Background:

• CRISPR/Cas9 technology, derived from bacterial defense systems, offers precise genome editing capabilities.
• It has emerged as a powerful tool in cancer immunotherapy, surpassing traditional gene editing methods.
• CRISPR/Cas9 specifically targets the PD-1/PD-L1 pathway in immune checkpoint blockade strategies.

Purpose of the Study:

• To review the development and applications of CRISPR/Cas9 in cancer immunotherapy.
• To highlight CRISPR/Cas9's role in immune checkpoint control and immune cell engineering.
• To discuss the current clinical trial status and future potential of CRISPR/Cas9 in cancer treatment.

Main Methods:

• Genomic editing via CRISPR/Cas9.
• Immune cell engineering for adoptive cell therapy.
• Targeting of PD-1/PD-L1 pathway for immune checkpoint blockade.

Main Results:

• CRISPR/Cas9 enables precise genomic modifications for enhanced cancer immunotherapy.
• The technology optimizes adoptive cell therapy by improving immune cell properties.
• CRISPR/Cas9 shows significant promise in targeting immune checkpoints.

Conclusions:

• CRISPR/Cas9 technology is a transformative tool in cancer immunotherapy, offering personalized treatment strategies.
• Further research is needed to address safety concerns, including off-target effects and unintended mutations.
• Continued advancements in CRISPR technology hold the potential to revolutionize cancer treatment paradigms.